Investment Rating - The report maintains a "Buy" rating for the company with a target price of 45.76 CNY, based on a projected 32 times price-to-earnings ratio for 2025 [3][6]. Core Insights - The company's revenue is expected to rebound due to stable prices of traditional carbon nanotube conductive pastes and strong growth in sales of new products, particularly single-walled carbon nanotubes [2][10]. - The demand for carbon nanotubes in the lithium battery market is increasing, with a penetration rate projected to reach 18.4% in 2024, up 8 percentage points year-on-year [10]. - The company is a leader in the carbon nanotube industry, holding nearly 50% market share in China, and is advancing its product development with a focus on high-performance materials [10]. Financial Summary - The company's projected revenue for 2024 is 1.449 billion CNY, with a slight increase of 3.2% year-on-year, followed by significant growth of 59.6% in 2025 [5][12]. - The net profit attributable to the parent company is forecasted to be 253 million CNY in 2024, down 14.8% from the previous year, but expected to rise to 495 million CNY in 2025 [5][12]. - The gross margin is projected to improve from 33.6% in 2023 to 38.0% in 2025, indicating a positive trend in profitability [5][12].

营收增速边际回升，息差韧性凸显 ——宁波银行 2024 年年报点评 核心观点 盈利预测与投资建议 ⚫ 结合财报数据，适度上调息差、下调非息收入增速等假设，预测公司 25/26/27 年归 母净利润同比增速为 6.8%/7.7%/8.7%，BVPS 为 35.01/38.75/42.82 元（25/26 年 前预测值 34.08/38.27 元），当前 A 股股价对应 25/26/27 年 PB 为 0.67/0.60/0.55 倍。公司近三年 PB（FY1）均值为 0.99倍，维持20%的折价幅度，对应 25年 0.79 倍 PB，目标价 27.75 元/股，维持"买入"评级。 风险提示 经济复苏不及预期；信贷需求不及预期；资产质量恶化。 公司主要财务信息 | 屈俊 | qujun@orientsec.com.cn | | --- | --- | | | 执业证书编号：S0860523060001 | | 于博文 | yubowen1@orientsec.com.cn | | | 执业证书编号：S0860524020002 | | | | 有关分析师的申明，见本报告最后部分。其他重要信息披露见分析师申明之后部 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 31.59 CNY based on a 27x P/E ratio for 2025 [2][5]. Core Views - The company's performance in 2024 is expected to be impacted by the demand rhythm in the equipment business and a reduction in government subsidies, but growth is anticipated to resume in 2025 [1]. - The revenue for 2024 is projected to decline by 2.7% to 2.45 billion CNY, with a recovery expected in subsequent years, reaching 2.89 billion CNY in 2025, 3.37 billion CNY in 2026, and 3.95 billion CNY in 2027 [4][10]. Financial Forecasts - Earnings per share (EPS) are forecasted to be 1.17 CNY in 2025, 1.35 CNY in 2026, and 1.59 CNY in 2027, with previous estimates adjusted downwards [2][4]. - The company’s gross margin is expected to stabilize around 48.3% in 2025, with net profit margins projected at 33.6% [4][10]. - The net profit attributable to the parent company is expected to recover to 970 million CNY in 2025, with further growth to 1.32 billion CNY by 2027 [4][10]. Revenue Breakdown - The report highlights a decline in carbon fiber revenue by 12.91% to 1.45 billion CNY, while carbon beam revenue increased by 25.81% to 537 million CNY [10]. - The T300 grade carbon fiber revenue is expected to drop significantly due to downstream equipment demand, while T800 grade revenue is projected to grow substantially as it begins mass supply [10]. Market Performance - The stock price as of April 8, 2025, was 27.46 CNY, with a 52-week high of 39.87 CNY and a low of 23.73 CNY [5]. - The company’s market capitalization is reported at 22.83 billion CNY [5].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 17.43 CNY [2][5]. Core Insights - The company is expected to achieve a net profit attributable to the parent company of 59.47 billion CNY, 82.68 billion CNY, and 101.25 billion CNY for the years 2024-2026, respectively. The average PE valuation of comparable companies for 2025 is 21 times [2]. - The company has experienced significant growth in sales, particularly in its new energy vehicle segment, with notable increases in the sales of its brands Deep Blue and Avita [1][10]. Financial Performance Summary - **Revenue**: The company reported revenues of 121.25 billion CNY in 2022, with projections of 151.30 billion CNY in 2023, 174.82 billion CNY in 2024, 194.29 billion CNY in 2025, and 213.01 billion CNY in 2026, reflecting a growth rate of 15.3% in 2022 and 24.8% in 2023 [4][11]. - **Net Profit**: The net profit attributable to the parent company was 7.80 billion CNY in 2022, expected to rise to 11.33 billion CNY in 2023, but projected to decline to 5.95 billion CNY in 2024 before recovering to 8.27 billion CNY in 2025 and 10.13 billion CNY in 2026 [4][11]. - **Earnings Per Share (EPS)**: EPS is projected to be 0.79 CNY in 2022, increasing to 1.14 CNY in 2023, but expected to drop to 0.60 CNY in 2024, before rising to 0.83 CNY in 2025 and 1.02 CNY in 2026 [4][11]. - **Profit Margins**: The gross margin is expected to decrease from 20.5% in 2022 to 16.1% in 2024, before slightly recovering to 18.0% by 2026 [4][11]. - **Return on Equity (ROE)**: The ROE is projected to decline from 13.2% in 2022 to 8.1% in 2024, with a recovery to 11.5% by 2026 [4][11].

Investment Rating - The report assigns an "Accumulate" rating for the company, with a target price of 21.06 CNY based on a 54 times P/E ratio for 2025 [3][6]. Core Views - The company is expected to experience rapid progress in its core business or key products over the next 1-2 years, with projected earnings per share of 0.26, 0.39, and 0.62 CNY for 2024-2026 [3]. - The company has a solid foundation as a comprehensive pharmaceutical enterprise, having established a research and development platform and acquired a pipeline of high-potential products [10][15]. - The treatment for vitiligo is scarce, and the company's CKBA product is anticipated to stand out in the market due to its unique mechanism and promising clinical trial results [10][50]. Financial Summary - The company's revenue for 2022 was 783 million CNY, with a projected decline to 757 million CNY in 2024, followed by a recovery to 951 million CNY in 2025 and 1,214 million CNY in 2026, reflecting a growth rate of 25.7% and 27.6% respectively [5]. - The net profit attributable to the parent company is expected to decrease from 175 million CNY in 2022 to 111 million CNY in 2024, before increasing to 165 million CNY in 2025 and 262 million CNY in 2026 [5]. - The gross margin is projected to improve from 58.2% in 2022 to 69.7% in 2026, indicating a positive trend in profitability [5]. Business Overview - The company started as an agent for gastrointestinal and ophthalmic medications and has gradually expanded into various fields, establishing a robust R&D platform since 2015 [10][15]. - The core business segments include gastrointestinal medications, sexual health products, and ophthalmic drugs, with stable growth in revenue from these areas [10][23]. - The company has significantly increased its R&D investment, leading to the development of important products such as dapoxetine and a rich pipeline of innovative drugs [32]. Market Opportunity - The prevalence of vitiligo is high, with over 12.33 million patients in China, and the demand for effective treatments is unmet, creating a significant market opportunity for CKBA [10][37]. - The competitive landscape for vitiligo treatments is favorable, with CKBA being the only non-JAK inhibitor drug in the domestic pipeline, currently in Phase II clinical trials [50][51].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 17.43 CNY [5][2]. Core Insights - The company is expected to achieve a net profit attributable to shareholders of 59.47 billion CNY, 82.68 billion CNY, and 101.25 billion CNY for the years 2024, 2025, and 2026 respectively, with a target price based on a 21x PE valuation [2]. - The company has seen significant growth in sales, particularly in its new energy vehicle segment, with notable increases in the sales of its brands Deep Blue and Avita [10][8]. Financial Performance Summary - **Revenue**: The company reported revenues of 121.25 billion CNY in 2022, with projections of 151.30 billion CNY in 2023, and expected growth to 174.82 billion CNY in 2024, 194.29 billion CNY in 2025, and 213.01 billion CNY in 2026, reflecting a growth rate of 15.3% in 2022 and 24.8% in 2023 [4][11]. - **Net Profit**: The net profit attributable to shareholders was 7.80 billion CNY in 2022, increasing to 11.33 billion CNY in 2023, but projected to decline to 5.95 billion CNY in 2024 before recovering to 8.27 billion CNY in 2025 and 10.13 billion CNY in 2026 [4][11]. - **Earnings Per Share (EPS)**: EPS is projected to be 0.79 CNY in 2022, increasing to 1.14 CNY in 2023, but expected to drop to 0.60 CNY in 2024, before rising to 0.83 CNY in 2025 and 1.02 CNY in 2026 [4][11]. - **Profit Margins**: The gross margin is expected to decline from 20.5% in 2022 to 16.1% in 2024, before slightly recovering to 18.0% by 2026 [4][11]. - **Return on Equity (ROE)**: ROE is projected to decrease from 13.2% in 2022 to 8.1% in 2024, with a gradual recovery to 11.5% by 2026 [4][11].

Investment Rating - The report gives the company an "Accumulate" rating for the first time, with a target price of 21.06 CNY based on a 54 times P/E ratio for 2025 [3][6]. Core Views - The company is expected to experience rapid progress in its core business or important products over the next 1-2 years, with projected earnings per share of 0.26, 0.39, and 0.62 CNY for 2024-2026 [3]. - The company has a solid foundation as a comprehensive pharmaceutical enterprise, having established a research and development platform and acquired a pipeline of high-potential products [10][15]. - The treatment for vitiligo is scarce, and the company's CKBA product is expected to stand out in the market due to its unique mechanism and promising clinical trial results [10][50]. Financial Information - The company's revenue for 2022 was 783 million CNY, with a projected revenue of 757 million CNY for 2024, followed by 951 million CNY in 2025 and 1,214 million CNY in 2026, reflecting a growth rate of 25.7% and 27.6% respectively [5]. - The net profit attributable to the parent company for 2022 was 175 million CNY, with projections of 111 million CNY for 2024, 165 million CNY for 2025, and 262 million CNY for 2026, indicating a significant growth trajectory [5]. - The gross margin is expected to improve from 58.6% in 2024 to 69.7% in 2026, while the net margin is projected to increase from 14.7% in 2024 to 21.6% in 2026 [5]. Business Overview - The company started as an agent and has developed into a comprehensive pharmaceutical enterprise, focusing on gastrointestinal, sexual health, and ophthalmic medications [10][15]. - The core products include "Hewei Zhengchang Wan" and "Woli Ting," with a strong emphasis on research and development to enhance product offerings [10][15]. - The company has significantly increased its R&D investment, leading to the successful development of key products like Dapoxetine and a rich pipeline of innovative drugs [32][34].

吉比特 603444.SH 公司研究 | 年报点评 | | 增持 （维持） | | --- | --- | | 股价（2025年04月08日） | 204.8 元 | | 目标价格 | 207.90 元 | | 52 周最高价/最低价 | 265.93/148.25 元 | | 总股本/流通 A 股（万股） | 7,204/7,204 | | A 股市值（百万元） | 14,754 | | 国家/地区 | 中国 | | 行业 | 传媒 | | 报告发布日期 | 2025 年 04 月 10 日 | | | 1 周 | 1 月 | 3 月 | 12 月 | | --- | --- | --- | --- | --- | | 绝对表现% | -9.3 | -10.18 | -0.24 | 18.78 | | 相对表现% | -3.21 | -2.74 | 3.41 | 15.55 | | 沪深 300% | -6.09 | -7.44 | -3.65 | 3.23 | | 项雯倩 | 021-63325888*6128 | | --- | --- | | 李雨琪 | xiangwenqian@orientsec. ...

公司主要财务信息 | | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 39,111 | 40,033 | 42,417 | 44,281 | 46,777 | | 同比增长 (%) | 7.2% | 2.4% | 6.0% | 4.4% | 5.6% | | 营业利润(百万元) | 4,831 | 5,712 | 6,050 | 6,653 | 7,328 | | 同比增长 (%) | 43.3% | 18.2% | 5.9% | 10.0% | 10.1% | | 归属母公司净利润(百万元) | 4,094 | 4,749 | 5,103 | 5,594 | 6,140 | | 同比增长 (%) | 36.4% | 16.0% | 7.5% | 9.6% | 9.8% | | 每股收益（元） | 2.29 | 2.66 | 2.86 | 3.14 | 3.44 | | 毛利率(%) | 26.5% | 27.9% | 28.9% | 29.4% | 29.8% | | ...